Crowley Wealth Management
BIB icon

Crowley Wealth Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Crowley Wealth Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,000
Closed -$50.7K – 409
2024
Q4 		$50.7K Buy
+1,000
New +$59.3K 0.04% 139

Other funds holding BIB

IMC Chicago
IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Chase Investment Counsel
Chase Investment Counsel Charlottesville, Virginia $479M AUM 81.51% 1-Year Est. Return
Westwood Wealth Management
Westwood Wealth Management Los Angeles, California $353M AUM 93.48% 1-Year Est. Return
Capital Investment Advisors
Capital Investment Advisors Atlanta, Georgia $7.74B AUM 15.52% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Park Square Financial Group
Park Square Financial Group Roswell, Georgia $8.79M AUM 9.68% 1-Year Est. Return

Crowley Wealth Management's BIB Position: Q1 2025 in Review

Crowley Wealth Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2025, closing a stake of 1,000 shares — an estimated $50.7K sold.

Crowley Wealth Management first reported a position in BIB in Q4 2024 and held it in 1 quarter. The position peaked at $50.7K in Q4 2024. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2025.

  • Crowley Wealth Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2025 after selling out during the quarter.
  • Crowley Wealth Management sold 1,000 ProShares Ultra NASDAQ Biotechnology shares in Q1 2025, an estimated $50.7K.
  • Crowley Wealth Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2024 and held it in 1 quarter.
  • Crowley Wealth Management's ProShares Ultra NASDAQ Biotechnology position peaked at $50.7K in Q4 2024.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2025.

Based on Crowley Wealth Management's 13F filing for Q1 2025, filed 16 Apr 2025.